In addition, in AML with inv(16) or t(16;16), p53 activity is inhibited via interactions between the inv(16) fusion protein CBFβ-SMMHC with HDAC8, where HDAC8 aberrantly deacetylates p53, which promotes leukemia. Here, TP53 is linked to leukemia.